BENITIONSClinical Trial Intelligence

Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neuromodulation in Depression

단계 해당 없음 완료 NCT05224063

대상 질환Major Depressive Disorder
임상 단계단계 해당 없음
스폰서Stanford University
상태완료
참여자 수50 명
중재(약물)Neuronavigated rTMS, Sham rTMS
시작일2023년 1월 1일
완료일2025년 3월 27일
결과 공개일2026년 7월 15일

요약

Depression is a highly prevalent condition characterized by persistent low mood, energy, and activity that can affect one's thoughts, mood, behavior, and sense of well-being. Repetitive transcranial magnetic stimulation (rTMS), a non-invasive neuromodulatory technique, is an effective treatment for depression when targeting the dorsolateral prefrontal cortex (dlPFC) of the central executive network (CEN). However, remission rates are suboptimal and individual methods to target the dlPFC are lacking. In this study, we will enroll 50 patients with major depression and in a single rTMS 'dose,' prospective, randomized, double-blind, cross-over design will assess whether rTMS targeted to an individual's central executive network (CEN) assessed by single pulse TMS can enhance network modulation. If successful, this work will lead to a clinical rTMS trial comparing this personalized targeting approach against standard rTMS.

Change in TMS-evoked EEG Responses Following Intermittent Theta Burst Stimulation (iTBS)

Pre-intervention and up to 20 minutes post-intervention · dBμV

Neuronavigated rTMS4.28 ± 0.58 dBμV
Sham rTMS3.95 ± 0.48 dBμV
Neuronavigated rTMS3.92 ± 0.53 dBμV
Sham rTMS4.28 ± 0.64 dBμV

BENITIONS에서 보기 ClinicalTrials.gov 원문 보기

같은 질환의 다른 임상

전체 임상

이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.